Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up periods reaching up to one year. The trial design included both a randomized withdrawal phase, allowing researchers to assess durability of effect and potential dependence concerns. Results from this scale of study carry meaningful clinical weight for patients who have not responded adequately to conventional pharmacologic options.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by providing high-level evidence for cannabis-derived treatment in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate inadequate efficacy and safety profiles. The rigorous design with 820 participants and extended follow-up enables clinicians to make evidence-based decisions about cannabis extracts as an alternative or adjunctive therapy for CLBP management. Given the opioid crisis and limitations of conventional analgesics, efficacy and safety data from this trial could reshape treatment algorithms for this prevalent condition.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents promising data for full-spectrum cannabis extract in chronic low back pain, a condition where current pharmacotherapy often disappoints patients and clinicians alike, though several considerations warrant careful interpretation before clinical adoption. The study’s strengths include its double-blind design and substantial sample size, yet the abstract’s truncation limits our ability to assess key outcomes, safety profiles, and whether observed benefits persist in the open-label extension or represent primarily placebo response patterns. Notably absent from this summary are details on the specific cannabinoid ratios in VER-01, baseline pain severity, functional outcomes, and comparative efficacy against conventional treatments like NSAIDs or physical therapy, all of which substantially influence clinical utility. For practitioners considering cannabis-based approaches in CLBP, this trial suggests potential value but should prompt review of the full manuscript to evaluate effect sizes, adverse event rates, drug interactions, and patient populations most likely to benefit before integrating VER-01 into treatment algorithms.